Introduction: Triglycyl lysine vasopressin (terlipressin, Glypressin®) is a potent vasoconstrictive drug which became popular because of its prolonged duration of action, ease of administration and lower incidence of side effects. Ischemic complications are rare but may be life threatening. Observations: Case 1, a 68-year-old man with alcoholic cirrhosis and hepatocellular carcinoma, was admitted due to acute functional renal failure. He was first treated for septic shock with intravenous catecholamines. He then developed hepatorenal syndrome and received terlipressin as intravenous bolus (4 mg/day). Three days later, he presented a diffuse purpuric and necrotic eruption with tongue ischemia. He died from Staphylococcus aureus infection. Case 2, a 74-year-old man with metastatic carcinoma, presented severe renal insufficiency. He developed sepsis and pseudohepatorenal syndrome, which was treated with terlipressin (0.5 mg/h) using an infusion pump. Four days later, he developed an isolated large erythematous and purpuric macular plaque of the scalp near skin metastases. The patient died a few weeks later from tumor progression. In both cases, skin biopsies showed ischemic necrosis caused by thrombosis of superficial dermal capillaries. Conclusion: These cases point to the risk of either widespread or localized necrosis. Although the precise incidence of these events as well as risk factors remain to be determined, hypovolemia, concomitant administration of vasoactive drugs and the mode of administration of terlipressin may influence the occurrence of these complications.

Keywords:
Drug side effects, Skin necrosis, Cancer, Terlipressin
1.
Kam PCA, Williams S, Yoong FFY: Vasopressin and terlipressin: pharmacology and its clinical relevance. Anesthesia 2004;59:993–1001.
2.
Ortega R, Gines P, Uriz J, et al: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941–948.
3.
Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK: Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J Gastroenterol Hepatol 2003;18:152–156.
4.
Delmas A, Leone M, Rousseau S, Albanese J, Martin C: Clinical review: vasopressin and terlipressin in septic shock patients. Crit Care 2005;9:212–222.
5.
Moreau R, Lebrec D: The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006;43:385–394.
6.
Halimi C, Bonnard P, Bernard B, et al: Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur J Gastroenterol Hepatol 2002;14:153–158.
7.
Colle I, Durand F, Pessione F, et al: Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with terlipressin: a retrospective analysis. J Gastroenterol Hepatol 2002;17:882–888.
8.
Moreau R, Durand F, Poynard T, et al: Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002;122:923–930.
9.
Willems MG, Schoenemann J, Rey C, Schäfer H, Lindecken KD: Ischemia of the cecum caused by glycylpressin. Leber Magen Darm 1985;15:165–168.
10.
Borrego R, Lopez-Herce J, Mencia S, Carillo A, Sancho L, Bustinza A: Severe ischemia of the lower limb and of the intestine associated with systemic vasoconstictor therapy and femoral arterial catheterization. Pediatr Crit Care Med 2006;7:267–269.
11.
Vaccaro F, Giorgi A, Riggio O, De Santis A, Laviano A, Rossi-Fanelli F: Is spontaneous peritonitis an inducer of vasopressin analogue side-effects? A case report. Dig Liver Dis 2003;35:503–506.
12.
Rosario R, Lalanne B, Lebre P, et al: Myocardial infarction after injection of terlipressin for digestive hemorrhage. Gastroenterol Clin Biol 1996;20:712–713.
13.
Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R: The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004;24:1050–1063.
14.
Hadengue A, Gadano A, Moreau R, et al: Beneficial effects of the 2-day administration of terlipresssin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998;29:565–570.
15.
Lipsker D, Kara F: Retiform purpura. N Engl J Med 2008;358:2.
16.
Dunser MW, Mayr AJ, Tur A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394–1398.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.